In Brief: warning letters, Emergen-C settlement, RapidMed expansion, CRN promotes MacKay
This article was originally published in The Tan Sheet
FDA cites unapproved OTC combination; pathogenic claims make supplement a drug; Direct Digital supports some claims; Alacer settles false advertising claim for Emergen-C; ScripsAmerica signs deal for RapiMed expansion; and CRN promotes MacKay.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.